Shanghai Taiwei Pharmaceutical Co., Ltd

The company's existing fixed assets of 10 million yuan, is an emerging private high-tech company. The company has newly built workshops that comply with GMP standards: 10,000-level and 100,000-level purification workshops, and has set up an equipment (annual output) of 10 tons of soybean phospholipid for injection. We have successively launched a series of products such as soybean lecithin for intravenous injection and soybean lecithin for high-purity fat milk. In July 1998, the company's intravenous soybean phospholipid project was recognized as the first batch of high-tech achievement transformation projects in Shanghai. In June 1999, he obtained the license of the pharmaceutical production enterprise, and in June 2001, the State Drug Administration approved the "Soybean Phospholipid Production Number for Injection". The project was also recognized as a key state-level key project by the Ministry of Science and Technology, and a 700,000 yuan innovation fund was allocated to encourage and support it. In 2000, on the basis of our company's separation and extraction process innovation, after a period of repeated trial production, the trial production of egg yolk phospholipids for injection was completed. In 2001, the process enlargement was completed, and the process equipment for mass production was successfully set up, and the PC content of its products can reach more than 95%. This is another industry-wide filling of domestic gaps.